CoChat

PAI-1 and Diabetes: A Journey From the Bench to the Bedside

Open access
Schneider, David J., Sobel, Burton E. · 2012 · Diabetes Care

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Abstract

D iabetologists have been well awaresince the seminal work ofHimsworth(1) in the 1930s that type 2 (insu-lin resistant) and type 1 (insulin defi-cient) diabetes were distinct entities with different pathophysiological bases. They have been aware for some time that type 2 diabetes is associated with resistance of tissues such as muscle and liver to the biological effects of in-sulin. Furthermore, they knew that type 2 diabetes per se and insulin resistance could both predispose to an increased risk of premature coronary artery dis-ease and particularly the premature oc-currence of myocardial infarction (MI). By contrast, cardiologists came to em-

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc12-0638

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Effects of increased concentrations of PAI-1. In blood (A) PAI-1 inhibits the action of t-PA, largely associated with clots, and thus attenuates the activity of the fibrinolytic system. In tissue (B), PAI-1attenuates activation of matrix metalloproteinases (MMPs) by plasmin generated from plasminogen by urokinase; plaques formed when PAI-1 is increased are likely to be prone to rupture. ECM, extracellular matrix; uPA, urokinase plasminogen activator.
Figure 1 Effects of increased concentrations of PAI-1. In blood (A) PAI-1 inhibits the action of t-PA, largely associated with clots, and thus attenuates the activity of the fibrinolytic system. In tissue (B), PAI-1attenuates activation of matrix metalloproteinases (MMPs) by plasmin generated from plasminogen by urokinase; plaques formed when PAI-1 is increased are likely to be prone to rupture. ECM, extracellular matrix; uPA, urokinase plasminogen activator.CC BY-NC-ND · PubMed Central
Figure 2 Increased PAI-1 concentration is demonstrated by the intensity of brown immunohistochemical staining of specimens of diseased coronary arteries from representative patients with type 2 diabetes (top row) when compared with similar specimens from representative patients without diabetes (bottom row). Negative controls, obtained with the use of normal murine IgG instead of primary antibody against PAI-1, showed no detectable staining (data not shown). Magnification ×100. The figure is adapted with permission from Sobel et al. (21). (A high-quality digital representation of this figure is available in the online issue.)
Figure 2 Increased PAI-1 concentration is demonstrated by the intensity of brown immunohistochemical staining of specimens of diseased coronary arteries from representative patients with type 2 diabetes (top row) when compared with similar specimens from representative patients without diabetes (bottom row). Negative controls, obtained with the use of normal murine IgG instead of primary antibody against PAI-1, showed no detectable staining (data not shown). Magnification ×100. The figure is adapted with permission from Sobel et al. (21). (A high-quality digital representation of this figure is available in the online issue.)CC BY-NC-ND · PubMed Central
Figure 3 Comparison of insulin-sensitizing (IS) with insulin-providing (IP) treatment strategies in 2,368 patients with type 2 diabetes and clinically stable coronary artery disease for an overall treatment interval of 5 years in the BARI 2D trial (44). The insulin-sensitizing strategy led to lower concentrations of both PAI-1 activity (A) and antigen (B). Baseline values for PAI-1 activity and PAI-1 antigen (16 AU/mL and 23 ng/mL, respectively) were the same for both the insulin-sensitizing and insulin-providing treatment groups.
Figure 3 Comparison of insulin-sensitizing (IS) with insulin-providing (IP) treatment strategies in 2,368 patients with type 2 diabetes and clinically stable coronary artery disease for an overall treatment interval of 5 years in the BARI 2D trial (44). The insulin-sensitizing strategy led to lower concentrations of both PAI-1 activity (A) and antigen (B). Baseline values for PAI-1 activity and PAI-1 antigen (16 AU/mL and 23 ng/mL, respectively) were the same for both the insulin-sensitizing and insulin-providing treatment groups.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 78

Metadata

Authors
Schneider, D. J., & Sobel, B. E.
Affiliations
University of Vermont (US)
Corresponding author
Schneider, David J.
Venue
Diabetes Care
Published
2012-09-11
Volume
35
Issue
10
Pages
1961-1967
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W1974895405
Cited by
78
References
50
Citations by year
2026: 5 · 2025: 2 · 2024: 5 · 2023: 6 · 2022: 9 · 2021: 4 · 2020: 4 · 2019: 6 · 2018: 6 · 2017: 7 · 2016: 4 · 2015: 8 · 2014: 1 · 2013: 9 · 2012: 2
FWCI
4.77
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Diabetes Care (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Disease and Adiposity
Keywords
plasminogen activator inhibitor-1, type 2 diabetes, type 1 diabetes, insulin resistance, myocardial infarction, coronary artery disease, cardiovascular risk, thrombosis
MeSH terms
Animals, Coronary Artery Bypass, Coronary Artery Disease, Diabetes Mellitus, Type 2, Fibrinolysis, Humans, Insulin, Insulin Resistance, Male, Myocardial Infarction, Obesity, Tissue Plasminogen Activator, Rabbits, Angioplasty, Balloon, Coronary, Randomized Controlled Trials as Topic, Plasminogen Activator Inhibitor 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.